

ASX Release

Suda Completes Acquisition of NovaDel Assets

Suda Ltd is delighted to announce that the acquisition of the NovaDel Pharma Inc. assets was completed earlier today.

Suda has now acquired the NovaMist™ technology and has rebranded the technology to SudaMist™. SudaMist™ is the proprietary system to deliver a broad range of marketed drugs through the highly absorptive lining of the mouth.

Suda now owns an extensive and robust patent portfolio with further patents pending. The patent portfolio covers over 300 pharmaceutical compounds and, importantly, the acquisition has resulted in Suda owning a strong clinically advanced product portfolio that is commercialisation ready. This portfolio includes oro-mucosal forms of delivery for:

- Erectile dysfunction (Sildenafil)
- Migraine headache (Sumatriptan)
- Chemotherapy induced nausea and vomiting (Ondansetron)
- Pre-procedural anxiety (Midazolam)
- Pulmonary arterial hypertension (Sildenafil)

Stephen Carter, Suda's Executive Chairman, stated that "Suda is further buoyed by the recent announcement regarding the upfront fee and milestone payments totalling in excess of \$110 million for a nasal delivery therapy for migraine using sumatriptan for the USA market (refer to optinose.com/news-and-media/press-releases/2013-07-02). It is acknowledged that oro-mucosal delivery is better accepted and more effective than nasal delivery and this announcement further supports that oro-mucosal products have great commercial potential and Suda is well placed to capitalise on this exciting drug delivery therapy".



Further information:
STEPHEN CARTER
EXECUTIVE CHAIRMAN
SUDA LTD

Tel: +61 8 6142 5555

sjcarter@sudaltd.com.au